<DOC>
	<DOC>NCT02154269</DOC>
	<brief_summary>The purpose of this study is to evaluate the effectiveness of treatment with G-CSF in patients with chronic heart failure secondary to Chagas disease.</brief_summary>
	<brief_title>Evaluation of G-CSF (Colony Stimulating Factor) in Patients With Chronic Chagas Cardiomyopathy</brief_title>
	<detailed_description />
	<mesh_term>Cardiomyopathies</mesh_term>
	<mesh_term>Chagas Cardiomyopathy</mesh_term>
	<mesh_term>Myocarditis</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<criteria>Diagnosis of Chagas' disease confirmed by two serological tests with different methodologies; Diagnosis of Chagas' cardiomyopathy in NYHA functional classes II, III and IV of heart failure; Availability and willingness to participate, given the schedule of the study; Agreement and signing the written form. Acute systemic infections Solid neoplasms, myelodysplastic syndrome, acute or chronic myeloid leukemia, confirmed by imaging studies or past medical history; Valvulopathies with hemodynamic consequences; Autoimmune, pulmonary, or degenerative diseases, confirmed by imaging studies or past medical history; Severe renal, hepatic or thyroid dysfunction, confirmed by imaging studies or past medical history; Pregnancy (confirmed by examination of Î² HCG) or lactation; Known hypersensitivity to GCSF or to other components of the formula and / or hypersensitivity to proteins derived from E. coli.</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Chagas disease</keyword>
	<keyword>G-CSF</keyword>
	<keyword>Cell therapy</keyword>
</DOC>